Myrexis to Present at 10th Annual JMP Securities Research Conference
03 mai 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian...
Myrexis to Hold Conference Call to Discuss Fiscal Third Quarter 2011 Financial Results
28 avr. 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, April 28, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will...
Myrexis Presents Data on Hsp90 Inhibitor Program at 102nd AACR Annual Meeting
05 avr. 2011 08h00 HE
|
Myrexis, Inc.
Potential for Combination With Other Targeted Cancer Therapies
Prodrug With Improved Characteristics Demonstrates Equivalent Efficacy
Evidence of Biological Activity in Patients
SALT LAKE...
Myrexis Presents Data on Cancer Metabolism Inhibitor Program at 102nd AACR Annual Meeting
05 avr. 2011 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, April 5, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it...
Myrexis Reorganizes to Align Resources With Current Pipeline
29 mars 2011 12h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, March 29, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced a...
Myrexis to Provide Update on Heat Shock Protein 90 and Cancer Metabolism Inhibitor Programs at 102nd Annual Meeting of American Association for Cancer Research
17 mars 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, March 17, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Present at 10th Annual Needham Healthcare Conference
16 mars 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, March 16, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Reports Second Quarter Fiscal 2011 Financial Results
09 févr. 2011 16h15 HE
|
Myrexis, Inc.
AzixaTM Two-Arm Phase 2b Study in Glioblastoma Initiated
Conference Call Today at 4:30pm EST
Upcoming Events
Report Phase 2 monotherapy results in recurrent glioblastoma multiforme (GBM)...
Myrexis Announces Azixa(TM) Clinical Data Publications
03 févr. 2011 09h00 HE
|
Myrexis, Inc.
Phase 1 Clinical Data Published by Molecular Cancer Therapeutics
Pre-Clinical, Phase 1 and 2 Clinical Data Review Published by Drugs of the Future
SALT LAKE CITY, Feb. 3, 2011 (GLOBE NEWSWIRE)...
Myrexis to Hold Conference Call to Discuss Fiscal Second Quarter 2011 Financial Results
01 févr. 2011 09h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...